Skip to main content
. 2020 May 4;22(1):145–154. doi: 10.3892/mmr.2020.11116

Figure 1.

Figure 1.

Dex-induced osteogenic inhibition in BMSCs. BMSCs were exposed to Dex (range, 10−9−10−6 M) for 7 days. (A) Reverse transcription-quantitative PCR was used to detect Runx2, ALP and OCN mRNA expression in BMSCs. (B) Western blotting was used to determine the Runx2 and ALP protein expression levels in BMSCs. (C) Relative ALP activity. (D) Cell Counting Kit-8 was used to assess the viability of BMSCs. (E) Alizarin red and ALP staining assays were used to measure the osteogenic function of BMSCs treated with 10−6 M Dex for 7 days. Scale bar, 20 µm. (F) Relative ALP activity of BMSCs treated with 10−6 M Dex for 7 days. All experiments were performed ≥3 times. ***P<0.001, **P<0.01, *P<0.05 and nsP≥0.05 vs. Veh. Dex, dexamethasone; BMSCs, bone mesenchymal stem cells; ALP, alkaline phosphatase; Runx2, Runt-related transcription factor 2; OCN, osteocalcin; Veh, vehicle.